Development of antiviral carbon quantum dots that target the Japanese encephalitis virus envelope protein

Chen, Han-Hsiang; Lin, Chin‐Jung; Anand, Anisha; Lin, Han‐Jia; Lin, Hung-Yun; Mao, Ju‐Yi; Wang, Peihua; Tseng, Yufeng J.; Tzou, Wen-Shyong; Huang, Chih‐Ching; Wang, Chia Hui

doi:10.1016/j.jbc.2022.101957

Cited by 25 publications

(18 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Figure 4A , the survival rate of RAW264.7 cells remained high viability even when the CDs nanozyme were cultured at relatively concentration reaching to 250 μg ml −1 . To verify whether CDs nanozyme exhibit anti-inflammatory ability, RAW264.7 cells were treated with lipopolysaccharide (LPS) to construct a classic cellular inflammation model ( Da Silva et al, 2019 ; Wang Z. et al, 2022 ; Chen et al, 2022 ; Kong et al, 2022 ). As shown in Figure 4B , the tumor necrosis factor- α (TNF- α ) level of CDs nanozyme + LPS (1 μg ml −1 ) group decreased significantly compared with that of LPS group.…”

Section: Resultsmentioning

confidence: 99%

Carbon dots nanozyme for anti-inflammatory therapy via scavenging intracellular reactive oxygen species

Dong

Huang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Developing an efficient antioxidant for anti-inflammatory therapy via scavenging reactive oxygen species (ROS) remains a great challenge owing to the insufficient activity and stability of traditional antioxidants. Herein, we explored and simply synthesized a biocompatible carbon dots (CDs) nanozyme with excellent scavenging activity of ROS for anti-inflammatory therapy. As expected, CDs nanozyme effectively eliminate many kinds of free radicals including •OH, O2•−, and ABTS+•. Benefiting from multienzyme activities against ROS, CDs nanozyme can decrease the levels of pro-inflammatory cytokines, resulting in good anti-inflammatory effect. Taken together, this study not only sheds light on design of bioactive antioxidants but also broadens the biomedical application of CDs in the treatment of inflammation.

show abstract

Section: Resultsmentioning

confidence: 99%

Carbon dots nanozyme for anti-inflammatory therapy via scavenging intracellular reactive oxygen species

Dong

Huang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“… 37 In 2022, Chen et al succeeded in showing that Cur-QDs have antiviral abilities against Japanese encephalitis virus (JEV). 38 In this study, Cur-QDs were able to bind directly to the E-S123/K312 site of the JEV protein, which inhibited the binding of the virus to the host cell.…”

Section: Introductionmentioning

confidence: 70%

“…Lin et al showed that curcumin-derived quantum dots (Cur-QDs) synthesized through a simple dry-heating treatment of curcumin can be used as an inhibitor of enterovirus 71 (EV71), with the inhibition process occurring during the replication process . In 2022, Chen et al succeeded in showing that Cur-QDs have antiviral abilities against Japanese encephalitis virus (JEV) . In this study, Cur-QDs were able to bind directly to the E-S123/K312 site of the JEV protein, which inhibited the binding of the virus to the host cell.…”

Section: Introductionmentioning

confidence: 99%

Theoretical Investigation of the Green-Synthesized Carbon-Based Nanomaterial Potential as Inhibitors of ACE2 for Blocking SARS-CoV-2 Binding

Sari,

Putri,

Paksi

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Since the emergence of SARS-CoV-2 in 2020, the world has faced a global pandemic, emphasizing the urgent need for effective treatments to combat COVID-19. This study explores the use of green-synthesized carbon-based nanomaterials as potential inhibitors of ACE2, a critical receptor for SARS-CoV-2 entry into host cells. Specifically, the study examines four carbon-based nanomaterials, namely, CD1, CD2, CD3, and CD4 in amino, graphitic, pyridinic, and pyrrolic forms, respectively, synthesized from curcumin, to investigate their binding affinity with ACE2. Molecular docking studies revealed that CD3 (pyridinic form) exhibited the highest binding affinity with ACE2, surpassing that of the control compound, curcumin. Notably, CD3 formed hydrophobic interactions and hydrogen bonds with key ACE2 residues, suggesting its potential to block the binding of SARS-CoV-2 to human cells. Moreover, molecular dynamics simulations demonstrated the stability of these ligand-ACE2 complexes, further supporting the promise of CD3 as an inhibitor. Quantum chemical analyses, including frontier molecular orbitals, natural bond orbital analysis, and the quantum theory of atoms in molecules, unveiled valuable insights into the reactivity and interaction strengths of these ligands. CD3 exhibited desirable chemical properties, signifying its suitability for therapeutic development. The study’s findings suggest that green-synthesized carbon-based nanomaterials, particularly CD3, have the potential to serve as effective inhibitors of ACE2, offering a promising avenue for the development of treatments against COVID-19. Further experimental validation is warranted to advance these findings and establish new therapies for the ongoing global pandemic.

show abstract

“…The guaiacol on the surface of curcumin-CQDs (CUR-CQDs), a nanomedicine synthesized by CQDs and curcumin, can bind to the JEV E DII and DIII via hydrogen bonding and Pi-cation interactions, respectively. In addition, compared to curcumin, Cur-CQDs have higher water solubility and lower cytotoxicity, and can reduce the production of reactive oxygen species (ROS) in cells, making it a promising alternative drug to curcumin [ 47 ].…”

Section: Antivirals Against Jev Infectionmentioning

confidence: 99%

Recent Advances in Antivirals for Japanese Encephalitis Virus

Zhu

Chen

Lurong

et al. 2023

Viruses

View full text Add to dashboard Cite

Culex mosquitoes are the primary vectors of the Japanese encephalitis virus (JEV). Since its discovery in 1935, Japanese encephalitis (JE), caused by JEV, has posed a significant threat to human health. Despite the widespread implementation of several JEV vaccines, the transmission chain of JEV in the natural ecosystem has not changed, and the vector of transmission cannot be eradicated. Therefore, JEV is still the focus of attention for flaviviruses. At present, there is no clinically specific drug for JE treatment. JEV infection is a complex interaction between the virus and the host cell, which is the focus of drug design and development. An overview of antivirals that target JEV elements and host factors is presented in this review. In addition, drugs that balance antiviral effects and host protection by regulating innate immunity, inflammation, apoptosis, or necrosis are reviewed to treat JE effectively.

show abstract

Development of antiviral carbon quantum dots that target the Japanese encephalitis virus envelope protein

Cited by 25 publications

References 88 publications

Carbon dots nanozyme for anti-inflammatory therapy via scavenging intracellular reactive oxygen species

Carbon dots nanozyme for anti-inflammatory therapy via scavenging intracellular reactive oxygen species

Theoretical Investigation of the Green-Synthesized Carbon-Based Nanomaterial Potential as Inhibitors of ACE2 for Blocking SARS-CoV-2 Binding

Recent Advances in Antivirals for Japanese Encephalitis Virus

Contact Info

Product

Resources

About